All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Treating Richter transformation in CLL

By Bryan Mc Swiney

Share:

Feb 13, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in CLL.


Richter transformation (RT), also known as Richter’s syndrome, is a rare complication of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). It is characterized by the development of an aggressive lymphoma from underlying CLL/SLL and carries a particularly poor prognosis, with an estimated median overall survival of 3–11 months. RT occurs in approximately 2–10% of patients with CLL/SLL, with the most common transformation being CD20+ diffuse large B-cell lymphoma (DLBCL). There is no standardized treatment strategy for patients with RT; therefore, a significant unmet need exists for safe and effective novel therapies.1,2

At the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in 2022, two abstracts were presented addressing the treatment of RT as part of a wider session on CLL. Below, the Lymphoma Hub is happy to present a summary of the key findings.

Subcutaneous epcoritamab in patients with Richter’s syndrome: early results from phase Ib/II trial (EPCORE CLL-1)1

Epcoritamab is a novel CD3 × CD20 bispecific antibody that has previously demonstrated encouraging clinical efficacy in patients with relapsed/refractory LBCL. Early data from the EPCORE CLL-1 (NCT04623541) trial also showed promising results in patients with relapsed/refractory CLL. Kater presented initial safety data from the RS-LBCL cohort of EPCORE CLL-1, which represents the first standalone dataset of a bispecific antibody for RT.

As of the data cutoff, ten patients with RT had received epcoritamab therapy with six patients receiving the drug as first-line therapy. Median treatment duration was 2.5 months and five patients received ongoing treatment. The most commonly reported treatment-emergent adverse events (TEAEs) of any grade were:

  • Grade 1 and 2 cytokine release syndrome (CRS; 90%)
  • anemia (40%)
  • diarrhea (40%)
  • hypophosphatemia (30%)
  • injection-site reaction (30%)
  • thrombocytopenia (30%)

Notable Grade 3/4 TEAEs included:

  • neutropenia (40%)
  • anemia (20%)
  • COVID-19 (20%)

All instances of CRS were resolved with no patients discontinuing treatment due to AEs or CRS. No patients experienced immune effector cell-associated neurotoxicity syndrome and two patients died due to disease progression. Antitumor activity was detected, with an overall response rate of 60% and a complete response rate (CRR) of 50%.

Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase I/II BRUIN study2

Pirtobrutinib is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor which has previously demonstrated inhibition of both wildtype and C481-mutant BTKs. In addition, pirtobrutinib has shown encouraging efficacy and a favorable safety profile in patients with poor-prognosis B-cell malignancies following prior therapy, including prior covalent BTK inhibitors. Shah presented data from the first sizeable cohort of RT patients included in the phase I/II BRUIN study (NCT03740529).

Out of a total of 82  patients with RT, 74 had received at least one prior RT-directed therapy. Among these patients, 75 were evaluable for response; the overall response rate was 52% with 10 complete responses and 29 partial responses. The median progression-free survival, overall survival, and duration of response was 3.7, 13.1, and 5.6 months in all patients with RT.

The safety portion of the trial found the most frequently reported TEAEs to be:

  • fatigue (26%)
  • diarrhea (22%)
  • confusion (19%)

The most frequent Grade ≥3 TEAEs was neutropenia (20%).

Conclusion

Overall, these data demonstrate both epcoritamab and pirtobrutinibs manageable safety profile and promising efficacy in patients with RT. Despite these encouraging findings, further studies are required to fully elucidate the clinical utility of these novel therapies for patients with RT.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

Your opinion matters

What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?